May 27, 2025 C-Path Welcomes Avidity Biosciences as Newest Member to Duchenne Consortium C-Path is excited to welcome Avidity Biosciences as a new member of the Duchenne Regulatory Science Consortium (D-RSC). Avidity is
April 17, 2025 RDCA-DAP Webinar: ACE Inhibitors as a Cardioprotective Treatment in Dystrophinopathies ACE inhibitors were the first pharmacological class shown to benefit heart failure treatment...
November 27, 2024 A computational tool to optimize clinical trial parameter selection in Duchenne muscular dystrophy: A practical guide and case studies Duchenne muscular dystrophy (DMD), a rare pediatric disease, presents numerous challenges when designing clinical trials...
June 29, 2018 Parent Project Muscular Dystrophy (PPMD) 2018 Annual Conference Jane Larkindale, Executive Director of D-RSC, attended the Parent Project Muscular Dystrophy (PPMD) 2018 Annual Conference in...
Critical Path Institute Receives Regulatory Support for Liver Injury Biomarker Tucson, AZ — January 22, 2018 — Critical Path Institute (C-Path) announced today that the European Medicines Agency (E
October 26, 2017 226th ENMC International Workshop: Towards Validated and Qualified Biomarkers for Therapy Development for Duchenne Muscular Dystrophy
C-Path and CDISC Announce Therapeutic Area User Guide for Duchenne Muscular Dystrophy October 18, 2017 TUCSON, Ariz., and AUSTIN, Texas – October 18, 2017 –Critical Path Institute (C-Path) and The
C-Path and CDISC Announce Public Review Period for Duchenne Therapeutic Area Standard June 13, 2017 TUCSON, Ariz., and AUSTIN, Texas – June 13, 2017 – The Clinical Data Interchange Standards Consort
